---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-020817"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:25:57.942542+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Bioxytran publishes positive peer-reviewed data for ProLectin-M and PLG-007 drug candidates

## Summary
- August 1, 2022 article in Int. J. Health Sciences: ProLectin-M blocks SARS-CoV-2 in vitro; all 5 COVID-19 patients achieved complete remission, zero hospitalization.
- July 13, 2022 article in Int. J. Molecular Science: PLG-007 component GMα competitively inhibits α-amylase, maltase, and lactase with Ki of 2.1×10^-6M.
- Press release issued August 1, 2022 announcing the ProLectin-M peer-reviewed article and supporting mechanism of action data.

## SEC filing metadata
- accession: 0001493152-22-020817
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315222020817/0001493152-22-020817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315222020817/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-020817
- JSON: https://secwatch.observer/filing/0001493152-22-020817.json
- Plain text: https://secwatch.observer/filing/0001493152-22-020817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.